全文获取类型
收费全文 | 18362篇 |
免费 | 1542篇 |
国内免费 | 551篇 |
专业分类
耳鼻咽喉 | 14篇 |
儿科学 | 2257篇 |
妇产科学 | 71篇 |
基础医学 | 1589篇 |
口腔科学 | 52篇 |
临床医学 | 2434篇 |
内科学 | 3580篇 |
皮肤病学 | 158篇 |
神经病学 | 158篇 |
特种医学 | 192篇 |
外国民族医学 | 5篇 |
外科学 | 204篇 |
综合类 | 2803篇 |
现状与发展 | 10篇 |
预防医学 | 407篇 |
眼科学 | 57篇 |
药学 | 1312篇 |
7篇 | |
中国医学 | 295篇 |
肿瘤学 | 4850篇 |
出版年
2024年 | 33篇 |
2023年 | 268篇 |
2022年 | 389篇 |
2021年 | 605篇 |
2020年 | 617篇 |
2019年 | 577篇 |
2018年 | 535篇 |
2017年 | 603篇 |
2016年 | 578篇 |
2015年 | 721篇 |
2014年 | 1123篇 |
2013年 | 1183篇 |
2012年 | 890篇 |
2011年 | 1094篇 |
2010年 | 776篇 |
2009年 | 788篇 |
2008年 | 778篇 |
2007年 | 741篇 |
2006年 | 704篇 |
2005年 | 675篇 |
2004年 | 672篇 |
2003年 | 497篇 |
2002年 | 444篇 |
2001年 | 441篇 |
2000年 | 327篇 |
1999年 | 320篇 |
1998年 | 313篇 |
1997年 | 235篇 |
1996年 | 313篇 |
1995年 | 317篇 |
1994年 | 290篇 |
1993年 | 261篇 |
1992年 | 248篇 |
1991年 | 224篇 |
1990年 | 175篇 |
1989年 | 187篇 |
1988年 | 183篇 |
1987年 | 135篇 |
1986年 | 114篇 |
1985年 | 215篇 |
1984年 | 167篇 |
1983年 | 106篇 |
1982年 | 133篇 |
1981年 | 104篇 |
1980年 | 83篇 |
1979年 | 91篇 |
1978年 | 61篇 |
1977年 | 48篇 |
1976年 | 46篇 |
1975年 | 13篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
2.
目的探究甲磺酸伊马替尼联合VDLD化疗方案治疗急性淋巴细胞白血病(ALL)患儿的应用价值。方法选取2015年5月~2018年6月收治的74例ALL患儿,按照治疗方案不同分组。对照组(37例)实施VDLD方案治疗,联合组(37例)实施甲磺酸伊马替尼+VDLD化疗方案治疗。对比两组疗效、不良反应发生率、随访1年无复发生存率(RFS)及治疗前、治疗2个疗程后血清B淋巴细胞刺激因子(BAFF)、增殖诱导配体(APRIL)水平。结果联合组总有效率(91.89%)高于对照组(72.97%)(P<0.05);联合组治疗2个疗程后血清BAFF、APRIL水平低于对照组(P<0.05);两组不良反应发生率、随访1年RFS对比无显著差异(P>0.05)。结论甲磺酸伊马替尼联合VDLD化疗方案治疗ALL,疗效确切,能显著降低血清BAFF、APRIL水平,且安全性高。 相似文献
3.
6-Mercaptopurine (6-MP) is commonly used for treatment of acute lymphoblastic leukemia (ALL). The incidence of hematotoxicity caused by this drug is quite high in Asians even using a standard low dosage regimen. The present study was aimed to elucidate the impact of thiopurine S-methyltransferase (TPMT), a nucleoside diphosphate-linked moiety X-type motif 15 (NUDT15), inosine triphosphatase (ITPA) and ATP Binding Cassette Subfamily C Member 4 (ABCC4) polymorphisms on hematotoxicity in pediatric patients who received a standard low starting dose of 6-MP. One hundred and sixty-nine pediatric patients were enrolled and their genotypes were determined. Patients who carried NUDT1513 and NUDT1512 genotypes were at a 10–15 fold higher risk of severe neutropenia than those of the wild-type during the early months of the maintenance phase. Risk of neutropenia was not significantly increased in patients with other NUDT15 variants as well as in patients with TPMT, ITPA or ABCC4 variants. These results suggest that NUDT15 polymorphisms particularly, NUDT1513 and NUDT1512, play major roles in 6-MP-induced severe hematotoxicity even when using a standard low dosage of 6-MP and genotyping of these variants is necessary in order to obtain precise tolerance doses and avoid severe hematotoxicity in pediatric patients. 相似文献
4.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献5.
6.
王鹏远 《中国继续医学教育》2021,(5)
目的评价血液科白血病疾病护理中应用健康教育的临床效果,为白血病护理工作提供参考。方法选择医院收治的白血病患者,总计60例。进行白血病患者随机分组护理,对照组与试验组各30例白血病患者,分别采取常规护理和常规护理+健康教育,比较2组白血病患者的负性情绪、自我效能状况评分以及护理满意度、护理依从率。结果试验组白血病患者干预后SAS、SDS、GSES评分均明显优于对照组,护理满意度与护理依从率均明显高于对照组,指标差异具有统计学意义,P>0.05。结论血液科白血病治疗期间配合落实常规护理、健康教育可以在提高患者自我效能的同时提高患者的依从性,符合患者身心护理需求,整体护理效果显著。 相似文献
7.
You-Wen Tan 《World Journal of Meta-Analysis》2021,9(6):488-495
Nilotinib is a specific breakpoint cluster region-Abelson leukemia virus-tyrosine kinase inhibitor that is used as an effective first- or second-line treatment in imatinib-resistant chronic myelogenous leukemia (CML) patients. Hepatotoxicity due to nilotinib is a commonly reported side effect; however, abnormal liver function test (LFT) results have been reported in asymptomatic cases. When alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels are more than five-fold the upper limit of the normal (ULN) or when the serum total bilirubin level is more than three-fold the ULN, dose modification or discontinuation of nilotinib is recommended, resulting in decreased levels of hematological indicators in certain patients with CML. Nilotinib-induced hyperbilirubinemia typically manifests as indirect bilirubinemia without elevated ALT or AST levels. Such abnormal liver functioning is thus not attributed to the presence of a true histologic lesion of the liver. The underlying mechanism may be related to the inhibition of uridine diphosphate glucuronosyltransferase activity. Therefore, nilotinib dose adjustment is not recommended for this type of hyperbilirubinemia, and in the absence of elevated liver enzyme levels or presence of abnormal LFT findings, physicians should consider maintaining nilotinib dose intensity without modifications. 相似文献
8.
9.
《Best Practice & Research: Clinical Haematology》2020,33(4):101220
Acute myeloid leukemia (AML) remains a therapeutically challenging malignancy with high rate of relapse and poor outcomes. There has been increased understanding of the molecular characteristics of AML and the various roles of the immune system in its pathogenesis, the result of which has led to the study and development of multiple immune-based approaches for this disease. In this review, we aim to provide an overview of the recent advancements made in antibody-based approaches to the treatment of AML including monoclonal antibodies, antibody-drug conjugates, and immune checkpoint inhibition. In addition, we provide insight and discuss the promise of these agents, some of which may soon enter the therapeutic armamentarium we currently employ against this lethal disease. 相似文献
10.
MPO和NAT2基因多态性与成人急性白血病易感性 总被引:2,自引:0,他引:2
目的研究髓过氧化物酶(MPO)和N-乙酰基转移酶2(NAT2)基因多态性与成人急性白血病易感性的关系.方法用1∶1配对病例-对照研究方法,收集成人急性白血病患者和对照各139例,应用聚合酶链-内切酶片段(PCR-RFLP)方法分析病例组和对照组MPO和NAT2的基因多态性,比较不同基因型与成人急性白血病易感性.结果 MPO-463A等位基因分布频率病例组低于对照组,MPO(G-463A)各基因型在病例组与对照组中的分布差异有统计学意义(χ^2=7.026,P〈0.05,OR=0.505,95%CI=0.325~0.847).NAT2乙酰化表型频率在病例组与对照组的分布差异无统计学意义(χ^2=2.260,P〉0.05);但NAT2*5 481T等位基因和NAT2*6 590A等位基因分布频率病例组高于对照组(P〈0.05).结论 MPO与成人急性白血病易感性相关,携带MPO(G-463A)突变基因型(GA/AA)个体可降低白血病的发病风险;NAT2乙酰化表型可能与白血病的易感性无关,但NAT2*5(C481T)、NAT2*6(G590A)单核苷酸突变频率病例组明显高于对照组. 相似文献